Shares of Northwest Biotherapeutics (NWBO) are poised for a strong up move at the open in response to its announcement that the Data Safety Monitoring Board recommends the continuation of its DCVax-L Phase 3 GBM trial.
The unblinded review was conducted in response to shareholder inquiries.
Prices have been on a roller coaster of late. In November, shares doubled, retraced, then shot up almost 150% to a February 27 peak of $7.92 before correcting. Shares closed yesterday at $5.96.